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Center and Harvard Medical School, 330 Brookline Avenue,
Boston, MA 02215, U.S.A.Mature human eosinophils have a polylobed nucleus with
condensed, marginated nuclear chromatin and, by electron
microscopy, are readily distinguished by their unique
granules (1). Thus, the bicompartmental specific (second-
ary) eosinophil granule is a membrane-bound organelle
divided into an outer matrix compartment and an inner,
electron-dense crystalline core compartment. In addition to
these large specific granules, smaller numbers of unicom-
partmental primary granules, osmiophilic lipid bodies,
small granules, and a diverse population of small vesicles
and elongated tubules exist in the cytoplasm of mature and
activated human eosinophils.
Immature human eosinophils undergo a complex series
of ultrastructural changes during maturation in vivo, or in
vitro (1,2). Characteristically, eosinophilic myelocytes (EM)
are large cells that undergo considerable size reduction as
the large, single nucleus condenses and segments, as
extensive cytoplasmic secretory organelles, such as dilated
cisterns of rough endoplasmic reticulum (RER) and Golgi
structures, are reduced in volume, as primary granules are
released, and as large immature, unicompartmental, homo-
geneously dense secondary granules are reduced in size and
undergo a shape change from round to spherical to become
bicompartmental. The crystallization of central cores with-
in these immature specific granules as well as their
immunogold profile [major basic protein [MBP]-positive,
Charcot-Leyden crystal protein (CLC-P)-negative] (3)
unequivocally identify this large immature granule popula-
tion as secondary granule precursors.
Activated eosinophils are a frequent inhabitant of tissues
in a wide variety of pathological processes, particularly
underlying mucosal surfaces of the respiratory, gastro-
intestinal and genito-urinary tracts. Activated tissue eosi-
nophils characteristically remain polymorphonuclear, often
assume motile shapes, and display increased numbers of*First presented at Eosinophil 1999, Lund, Sweden.
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secondary granules release matrix and/or core compart-
ment contents, or are released in their entirety, from cells.
In the first case, activated eosinophils display a complete
complement of empty and partially empty secondary
granules, a process we have termed piecemeal degranula-
tion (PMD) (4,5), to distinguish it from the extrusion of
entire granules from the cell (6). When an endogenous
secondary granule matrix protein, eosinophil peroxidase
(EPO), was imaged with a cytochemical method, EPO-
containing, smooth membrane-bound vesicles were at-
tached to secondary granules and plasma membranes and
were free in the intervening cytoplasm in both mature and
immature eosinophils arising in growth factor-supplemen-
ted cultures of human cord blood mononuclear cells (5).
These EPO-loaded vesicles serve as a vesicular transport
mechanism for effecting PMD of a secondary granule
matrix protein, EPO, from human eosinophils.
We have examined the distribution of CLC-P, an
eosinophil primary granule protein (7) in activated human
eosinophils and their environment in vivo (8,9) and in vitro
(3–5) with and without double imaging provided by
concomitant cytochemical detection of EPO (5). While
tissue areas in eosinophil necrosis-packed lesions were rich
in CLC-P (8), vesicular transport of CLC-P was not evident
from eosinophils concomitantly undergoing PMD of a
secondary granule matrix protein, EPO, in vitro (5). Rather,
the distribution of CLC-P in activated eosinophils was
diffuse in the cytoplasm and nucleus, present in primary
granules and absent from secondary granules regardless of
the degree of PMD of this granule population (4,5,8,9).
Thus, CLC-P is absent from secondary granules and is not
secreted from activated eosinophils by vesicular transport.
In contrast, CLC-P is secreted by vesicular transport in
activated human basophils undergoing PMD (reviewed in
ref. 10). Thus, while both eosinophils and basophils contain
subcellular sites of CLC-P, the sites and the kinetics and
mechanisms of release differ substantially between these
two granulocyte classes.
Human eosinophil granules include a large number of
bicompartmental secondary granules and a small number
of unicompartmental primary granules in mature cells [Fig.
1(A)]. Mature primary granules in mature human eosino-
phils were discovered when an immunogold analysis
detected CLC-P within them (7) [Fig. 1(A)]. Both immature
primary and secondary granules exist in immature eosino-
phils. In mature secondary granules, the eosinophil granule
proteins EPO, eosinophil-derived neurotoxin (EDN) and
eosinophil cationic protein (ECP) are localized to the
matrix compartment, and MBP to the core compartment
by immunogold analysis (reviewed in ref. 1). It is now clear
that eosinophils synthesize, store and secrete a large
number of cytokines (reviewed in ref. 11). The first of these# 2000 HARCOURT PUBLISHERS LTD
Fig. 1. Immunogold preparations of human eosinophil
granules. In A, the unicompartmental mature primary
granule is labelled for CLC-P; a mature bicompartmental
secondary granule does not label for CLC-P in this
mature, peripheral blood eosinophil. In B, a
unicompartmental secondary granule is labelled for MBP;
In C, a unicompartmental secondary granule is not
labelled for CLC-P in the same preparation of eosinophils
arising from cord blood cells cultured with rhIL-5 (B and
C, with permission, ref. 3).
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necrosis factor-alpha (TNF-a)—is also a matrix component
of secondary granules (12), as is transforming growth
factor-alpha (TGF-a) (13). Mature primary granules are
large unicompartmental structures which contain CLC-P,
as is true for their immature counterparts (3,7). They do not
represent oblique cuts through the matrix compartment of
secondary granules, since CLC-P is absent from the matrix
compartment of all bicompartmental secondary granules
(7) [Fig. 1(A)]. Previous biochemical analyses of the
lysophospholipase activity of CLC-P also did not detect
CLC-P in secondary granule subcellular fractions (14).
Secretion of primary granules from immature eosinophils in
bone marrow samples by classical exocytosis has been
recorded (1,2,15) and probably accounts for the marked
reduction in this granule population in mature cells.
Activated mature human eosinophils which developed in
vitro from cultured cord blood cells had increased numbers
of unicompartmental large granules that were indistinguish-
able from primary granules in routine ultrastructural
preparations (3) [Fig. 1(B,C)]. Use of granule markers for
secondary granule matrix (EPO), for secondary granule
core (MBP) and for primary granules (CLC-P) demon-
strated that these granules did not contain CLC-P [Fig.
1(C)] and, thus, were not primary granules. They stained
uniformly for MBP (3) [Fig. 1(B)].Eosinophilic myelocytes contain large numbers of
immature secondary granules (1). These structures are
large, round, homogeneously dense, unicompartmental
granules that contain admixed MBP and EPO but do not
contain CLC-P (3). Each eosinophilic myelocyte has some
immature secondary granules that are becoming bicom-
partmental and within which central condensation and
crystallization of MBP-containing cores are evident (3). As
these changes occur, the unicompartmental immature
secondary granule elongates and becomes spherically
shaped, like the shape of bicompartmental mature second-
ary granules.
Bicompartmental mature secondary granules can become
unicompartmental in mature human eosinophils (3). This
occurs in PMD when secretory vesicles transport all matrix
proteins (e.g. EPO) out of the secondary granules (3). The
resultant unicompartmental secondary granules, prevalent
in activated mature cells, are uniformly immunogold-
labeled for MBP [Fig. 1(B)] but are devoid of EPO (3).
These altered secondary granules do not contain CLC-P (3)
[Fig. 1(C)]. Emptying of the core compartment (but not the
matrix compartment) from secondary granules would result
in unicompartmental, EPO-positive/MBP-negative/CLC-P-
negative granules. Single sections that traverse matrix
compartments only of bicompartmental secondary granules
would also have this labeling profile. Before considering
any of these as persistent unicompartmental primary
granules in activated cells, the labeling profile should be
EPO-positive/MBP-negative/CLC-P-positive; granules with
this profile have not been identified (3,16,17). On balance,
the morphological, cytochemical and immunogold profiles
of human eosinophil granule populations support a model
of separate primary and secondary granules, each with their
individual immature granule precursors.
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The most characteristic feature of eosinophils is their
content of highly cationic proteins, stored in cytoplasmic
granules. The main components of these so-called specific
granules are major basic protein (MBP), eosinophil
peroxidase (EPO), eosinophil-derived neurotoxin/eosino-
phil protein X (EDN/EPX) and eosinophil cationic protein
(ECP). The mechanisms involved in their release and their
functions in microbe-containing phagosomes or in the
extracellular environment may hold keys to many hitherto
unanswered questions relating to the roles of eosinophils in
host defense and inflammation.
Eosinophils were long considered mainly secretory cells,
releasing their granule content onto the surfaces of multi-
cellular parasites or into the extracellular environment.
However, they are also, especially after activation, capable
of phagocytosing bacteria, and can release their granule
contents into phagosomes where they can exert cytotoxic
effects [Fig. 1(A)]. In experimental models for the study of
binding and phagocytosis by eosinophils, serum-treated
zymosan (STZ) can be used. The binding of STZ to
eosinophils is mainly dependent on a receptor belonging to
the b2-integrin family of adhesion molecules, namely
complement receptor 3 (CR3, also called CD11b/CD18 or
Mac-1) (1). Eosinophil binding of STZ increases after
pretreatment (priming) with several agents, among them
platelet-activating factor (PAF), interleukin-3 (IL-3), IL-5,
granulocyte/macrophage-colony stimulating factor (GM-
CSF) (1), and tumour necrosis factor (TNF)-a (2). This
priming process increases the anity of CR3 for its ligand
(iC3b) on the particles.
Quantitative evaluation of eosinophil degranulation is
easiest to perform in assays where non-phagocytosable
surfaces are a target for release and granule contents can be
measured in the surrounding medium. Using such an assay
we have shown that activation of protein kinase C by PMA
induces ECP release in eosinophils adherent to a surface.
This release is dependent on signalling by b2-integrins (3).
Platelet-activating factor and GM-CSF also induce degra-
nulation shown to be dependent on a b2-integrin, i.e. CR3
(4). In addition, immobilized immunoglobulin induces
eosinophil degranulation that involves cooperative signal-
ling by CR3 (5).
We have used serum-opsonized Sephadex (SOS), which
represents a semi-physiological parasite model, to investi-
gate release of ECP from eosinophils [Fig. 1(B)]. The
release in this system is also mainly dependent on binding
and signalling through CR3 (2). Priming of eosinophils
with IL-5 or TNF-a increases ECP release in response to
